[Onasemnogene abeparvovec (spinal muscular atrophy with >= 4 copies of the SMN2 gene and SMA Type 2, Type 3, Type 4 or of undefined type, >= 2 years) – Benefit assessment according to §35a Social Code Book V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018016149
German
Original Title:
Onasemnogen abeparvovec (spinale Muskelatrophie mit ≥ 4 Kopien des SMN2-Gens und SMA Typ 2, Typ 3, Typ 4 bzw. ohne definierten Typ, ≥ 2 Jahre)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a26-99.html
Year Published:
2026
URL for published report:
https://www.iqwig.de/download/a26-99_onasemnogen-abeparvovec_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Muscular Atrophy, Spinal
- Genetic Therapy
- Biological Products
- Recombinant Fusion Proteins
Keywords
- Onasemnogene abeparvovec
- Muscular Atrophy – Spinal
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.